Background
Baxalta (a Takeda subsidiary) holds U.S. Patent No. 7,033,590, directed to antibodies that bind to and enhance the activity of Factor IX or Factor IXa — clotting factors essential for blood coagulation. The patent was directed at treatments for hemophilia A, a serious bleeding disorder. Genentech and Chugai Pharmaceutical developed emicizumab (Hemlibra), a bispecific antibody that bridges Factor IX and Factor X, effectively mimicking the function of Factor VIII (which hemophilia A patients lack). Hemlibra became a blockbuster treatment, representing a major advance in hemophilia care.
Baxalta sued Genentech, arguing Hemlibra fell within the scope of its antibody patent. The critical question was what the term “antibody” meant in the claims. Genentech argued for a narrow construction limited to conventional two-heavy-chain, two-light-chain immunoglobulins, which would exclude bispecific antibodies like Hemlibra. The district court adopted Genentech’s construction and granted summary judgment of noninfringement. Baxalta appealed.
The Court’s Holding
The Federal Circuit vacated and remanded. Applying the principle that claim terms are construed primarily by reference to the intrinsic record (the claim language, specification, and prosecution history), the court found the district court had adopted an unduly narrow construction of “antibody.” The patent’s specification, while containing a general introduction to antibody structure, also explicitly disclosed bispecific antibodies, chimeric antibodies, and humanized antibodies as forms of “antibodies of the present invention.” Choosing a narrow construction that excluded these specifically disclosed forms was inconsistent with the written description.
The Federal Circuit held the term “antibody” was broad enough to encompass bispecific antibodies like Hemlibra. On remand, the district court would need to reconsider infringement under the broader construction. (In subsequent proceedings, the patent was ultimately found invalid for lack of enablement.)
Key Takeaways
- Claim terms must be construed consistent with the full written description — if a specification explicitly discloses multiple variants as falling within the invention, a construction that excludes them may be too narrow.
- For biologic drug patents, the breadth of terms like “antibody” can determine whether next-generation engineered biologics (such as bispecific antibodies) fall within the patent’s scope.
- Patent applicants drafting antibody patents should clearly and specifically disclose all antibody formats (mono-, bi-, and multispecific; humanized; chimeric) intended to be covered, and use claim language that consistently reflects that scope.
- Narrow claim construction in early litigation can create exposure for reversal on appeal if the specification tells a broader story.
Why It Matters
Bispecific antibodies represent a major advance in biologic drug design — instead of binding a single target, they bridge two different molecules, enabling new mechanisms of therapeutic action. Hemlibra was the first bispecific antibody approved for hemophilia and transformed treatment for patients with Factor VIII inhibitors. The question of whether existing antibody patents cover novel bispecific formats is commercially enormous, as the bispecific antibody market is valued in the tens of billions of dollars.
Baxalta v. Genentech illustrated how pivotal claim construction can be in disputes between existing patent holders and next-generation biologic developers. The decision also underscored the importance of enabling and describing all anticipated antibody formats in the original patent specification, rather than relying on narrow examples that may not support broad claims against future innovations.